These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29986747)

  • 1. Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1).
    Jiang W; Ye S; Xiang L; Yang W; He T; Pei X; Guo L; Yang H
    J Ovarian Res; 2018 Jul; 11(1):58. PubMed ID: 29986747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
    Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
    Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment and characterization of a cell line (HCH-1) originating from a human clear cell carcinoma of the ovary.
    Yamada T; Hattori K; Satomi H; Okazaki T; Mori H; Hirose Y
    J Ovarian Res; 2016 Jun; 9(1):32. PubMed ID: 27259990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
    Kim M; Lu F; Zhang Y
    Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of a human ovarian clear cell carcinoma cell line mutant in PIK3CB but not PIK3CA.
    Hoshino H; Inoue D; Shinagawa A; Yoshida H; Shigeto S; Matsuda K; Akama TO; Yoshida Y; Kobayashi M
    Hum Cell; 2024 Jul; 37(4):1184-1193. PubMed ID: 38573494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations.
    Huang HN; Huang WC; Lin CH; Chiang YC; Huang HY; Kuo KT
    Hum Pathol; 2014 Nov; 45(11):2318-25. PubMed ID: 25281027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression.
    Sato S; Itamochi H; Oumi N; Chiba Y; Oishi T; Shimada M; Sato S; Chikumi J; Nonaka M; Kudoh A; Komatsu H; Harada T; Sugiyama T
    Hum Cell; 2016 Oct; 29(4):181-7. PubMed ID: 26960408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
    Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
    Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
    Su YF; Tsai EM; Chen CC; Wu CC; Er TK
    Clin Chim Acta; 2019 Jul; 494():1-7. PubMed ID: 30851247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
    Caumanns JJ; Berns K; Wisman GBA; Fehrmann RSN; Tomar T; Klip H; Meersma GJ; Hijmans EM; Gennissen AMC; Duiker EW; Weening D; Itamochi H; Kluin RJC; Reyners AKL; Birrer MJ; Salvesen HB; Vergote I; van Nieuwenhuysen E; Brenton J; Braicu EI; Kupryjanczyk J; Spiewankiewicz B; Mittempergher L; Bernards R; van der Zee AGJ; de Jong S
    Clin Cancer Res; 2018 Aug; 24(16):3928-3940. PubMed ID: 29685880
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
    Huang HN; Chiang YC; Cheng WF; Chen CA; Lin MC; Kuo KT
    Mod Pathol; 2015 Feb; 28(2):303-11. PubMed ID: 25081752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
    Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
    J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma.
    Rahman MT; Nakayama K; Rahman M; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
    Cancer; 2012 Jun; 118(11):2846-57. PubMed ID: 22139760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy.
    Yamashita Y
    Jpn J Clin Oncol; 2015 May; 45(5):405-7. PubMed ID: 25583423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
    Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
    Virchows Arch; 2012 Jan; 460(1):77-87. PubMed ID: 22120431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer.
    Er TK; Su YF; Wu CC; Chen CC; Wang J; Hsieh TH; Herreros-Villanueva M; Chen WT; Chen YT; Liu TC; Chen HS; Tsai EM
    J Mol Med (Berl); 2016 Jul; 94(7):835-47. PubMed ID: 26920370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
    Berns K; Caumanns JJ; Hijmans EM; Gennissen AMC; Severson TM; Evers B; Wisman GBA; Jan Meersma G; Lieftink C; Beijersbergen RL; Itamochi H; van der Zee AGJ; de Jong S; Bernards R
    Oncogene; 2018 Aug; 37(33):4611-4625. PubMed ID: 29760405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks.
    Murakami R; Matsumura N; Brown JB; Higasa K; Tsutsumi T; Kamada M; Abou-Taleb H; Hosoe Y; Kitamura S; Yamaguchi K; Abiko K; Hamanishi J; Baba T; Koshiyama M; Okuno Y; Yamada R; Matsuda F; Konishi I; Mandai M
    Am J Pathol; 2017 Oct; 187(10):2246-2258. PubMed ID: 28888422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma.
    Li S; Meersma GJ; Kupryjanczyk J; de Jong S; Wisman GBA
    J Transl Med; 2024 Jun; 22(1):556. PubMed ID: 38858765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
    Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.